Reuters
ZURICH, Feb 25 () - Swiss drugmaker Novartis said on Monday it is exercising its option to license rights to an investigational, RNA-targeting cardiovascular drug from Ionis Pharmaceuticals as it targets inherited factors that have defied other treatments.
"We're excited about the novel, RNA-targeting approach that could be a gamechanger for people with elevated Lp(a)," said John Tsai, Novartis's drug development head. "If our Phase 3 trial succeeds, we expect that TQJ230 will become the leading treatment option."
OCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
ZURICH, Feb 25 () - Swiss drugmaker Novartis said on Monday it is exercising its option to license rights to an investigational, RNA-targeting cardiovascular drug from Ionis Pharmaceuticals as it targets inherited factors that have defied other treatments.
"We're excited about the novel, RNA-targeting approach that could be a gamechanger for people with elevated Lp(a)," said John Tsai, Novartis's drug development head. "If our Phase 3 trial succeeds, we expect that TQJ230 will become the leading treatment option."
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
